KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Net Income (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Net Income for 13 consecutive years, with -$105.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income fell 48.93% to -$105.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$345.9 million, a 44.54% decrease, with the full-year FY2025 number at -$345.9 million, down 44.54% from a year prior.
  • Net Income was -$105.3 million for Q4 2025 at Xenon Pharmaceuticals, down from -$90.9 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$15.4 million in Q3 2021 to a low of -$105.3 million in Q4 2025.
  • A 5-year average of -$48.2 million and a median of -$44.6 million in 2023 define the central range for Net Income.
  • Peak YoY movement for Net Income: tumbled 12533.71% in 2021, then increased 2.26% in 2023.
  • Xenon Pharmaceuticals' Net Income stood at -$25.6 million in 2021, then tumbled by 46.28% to -$37.4 million in 2022, then rose by 2.26% to -$36.5 million in 2023, then tumbled by 93.37% to -$70.7 million in 2024, then crashed by 48.93% to -$105.3 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Net Income are -$105.3 million (Q4 2025), -$90.9 million (Q3 2025), and -$84.7 million (Q2 2025).